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Objectives. We sought to examine the relation between time to
treatment and 90-min patency rates in patients receiving intrave-
nous streptokinase (SK) or accelerated tissue-type plasminogen
activator (t-PA).
Background. Early patency of the infarct-related artery is a
major determinant of survival after thrombolysis for acute myo-
cardial infarction. Some data suggest that time to treatment may
influence the efficacy of nonfibrin-specific thrombolytic agents in
restoring early patency of the infarct-related vessel.
Methods. We performed a retrospective analysis of a cohort of
481 patients receiving thrombolytic therapy for acute myocardial
infarction <6 h after pain onset, all of whom underwent 90-min
coronary angiography. Patency of the infarct-related artery was
graded by two observers who had no knowledge of the treatment
received or the time between pain and therapy.
Results. There was no difference in baseline clinical or angio-
graphic characteristics according to the timing or nature of
treatment. Thrombolysis in Myocardial Infarction (TIMI) flow
grade 2 or 3 patency rate after SK correlated negatively with the
time between onset of pain and thrombolysis (r 5 0.8, p 5 0.05),
whereas the 90-min patency rate after t-PA appeared stable as a
function of time to treatment. When patients were categorized as
having received treatment <3 or >23 h after pain onset, the
patency rate was similar with t-PA, but significantly higher when
SK was administered early rather than late, regardless of whether
TIMI flow grades 2 and 3 were pooled (86.9% vs. 59.4%, p 5
0.0001) or TIMI flow grade 3 alone was considered to indicate
patency (81.7% vs. 53.6%, p 5 0.0001). Multivariate logistic
regression analysis showed a negative effect of time to treatment on
the patency probability for SK (p 5 0.0001) but not for t-PA.
Conclusions. The efficacy of streptokinase but not t-PA in
restoring early coronary patency after intravenous thrombolysis is
markedly lower when patients are treated later after onset of pain.
(J Am Coll Cardiol 1998;31:776–9)
©1998 by the American College of Cardiology
Early (60 to 90 min) and complete (i.e., Thrombolysis in
Myocardial Infarction [TIMI] flow grade 3) patency of the
infarct-related artery is a major determinant of survival after
thrombolysis for acute myocardial infarction (1–3). Several
studies have suggested that, at least with nonfibrin-specific
thrombolytic agents, time to treatment may influence the
patency rates achieved at 90 min (4–6). We examined differ-
ences between thrombolysis with streptokinase (SK) and
tissue-type plasminogen activator (t-PA) with regard to 90-min
patency, according to the timing of treatment after pain onset.
Methods
This retrospective analysis was based on data from two
recent prospective French studies of coronary patency after
thrombolysis (7,8), involving two cohorts of consecutive pa-
tients receiving intravenous thrombolysis for acute myocardial
infarction ,6 h after symptom onset and who underwent
routine 90-min coronary angiography, regardless of clinical
and electrocardiographic signs of reperfusion. Patients were
enrolled if they met the following criteria: nitrate-resistant
chest pain of #6 h but .30 min duration; ST segment
elevation or giant T waves or left bundle branch block; and no
contraindication to thrombolysis. All the patients received at
least 250 mg of aspirin followed by either SK (1.5 million U
intravenously over 60 min) or accelerated t-PA (15-mg bolus
followed by 0.75 mg/kg body weight in 30 min [maximum
50 mg] and 0.50 mg/kg over 60 min [maximum 35 mg]). The
choice of the agent was left to the discretion of the attending
physician. Seventy-two additional patients who had received
other thrombolytic regimens were excluded from the analysis.
All the patients underwent 90-min coronary angiography, with
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a bolus of at least 5,000 IU heparin intravenously at the
beginning of the procedure. All angiograms were recorded on
35-mm cine film and were analyzed off-line by two independent
observers from a group of five experienced angiographers who
had no knowledge of the treatment received nor the time
between pain onset and therapy. The infarct-related artery
could not be ascertained in eight patients, so these patients
were excluded from the analysis. In all other cases, flow in the
infarct-related vessel was graded according to the TIMI score,
with discrepancies being resolved by consensus. Patency was
graded after at least four injections of dye through the
infarct-related vessel and, in patients with systolic blood pres-
sure $100 mm Hg, after intracoronary injection of nitrates.
Multivessel disease was defined as a lumen diameter reduction
of at least 50% in at least two major epicardial arteries.
Statistical analysis. All continuous variables are presented
as the mean value 6 SD. Comparisons of baseline character-
istics were based on the Student t test for continuous variables
and the chi-square test for categoric variables. A p value ,0.05
was used to denote statistical significance. To investigate the
relation between early patency, treatment and time to throm-
bolysis, multivariate analysis was performed using the SAS
statistical package (SAS Institute). This analysis was based on
the logistic model and involved two steps: in the first step, there
was a model expressing the probability of early patency as a
logistic function of three potential factors—namely, the throm-
bolytic agent used, the time to thrombolysis and an interaction
term. The values of the variables for each factor were com-
pared with zero using the Wald test (9,10). In the second step,
a final model was derived from the initial model by discarding
the factors that were not linked to patency.
Results
Four hundred eighty-one patients were analyzed, 237 of
whom received t-PA and 244 of whom received SK. Their
baseline characteristics were similar (Table 1). Coronary an-
giography was performed 90 min after the start of thrombolysis
in every patient and found single-vessel disease in 53.8% and
56.2% of patients receiving t-PA and SK, respectively (p 5 NS).
In-hospital deaths occurred in 5.4% and 2.3% of patients
receiving t-PA and SK, respectively (p 5 NS). TIMI flow grade
2 or 3 patency was achieved in 72.6% and 77.4% of patients
treated with t-PA and SK, respectively (p 5 NS). The TIMI
flow grade 2 or 3 patency rate after SK correlated negatively
with the time between the onset of pain and the beginning of
thrombolysis (r 5 0.8, p 5 0.05), whereas the 90-min patency
rate after t-PA was stable (Fig. 1).
Figure 1 suggests that the effect of time on probability of
patency is different for the two thrombolytic agents. This
hypothesis was confirmed by multivariate logistic regression
analysis. The variables estimated from the initial model and
the p values derived from the Wald test are displayed in Table
2A. This table shows a significant effect of the type of
treatment (SK or t-PA) and of the treatment–time interaction,
but the effect of time was not significant. Therefore, this last
variable was discarded from the final model displayed in Table
2B: for patients receiving SK (coded 1), the probability of
patency is a logistic function of a term expressed as: (intercept
variable 1 treatment variable 1 interaction variable 3 time to
treatment). Because the latter is significantly lower than zero,
this means that for these patients, the probability of patency
decreases when time to treatment increases. In contrast, for
patients receiving t-PA, the probability of patency is only a
function of the intercept variable (because t-PA was coded 0,
it nullifies the treatment and the interaction terms). Therefore,
at least within 6 h of pain onset, the effect of time to treatment
Abbreviations and Acronyms
PERM 5 Prospective Evaluation of Reperfusion Markers study
SK 5 streptokinase
TIMI 5 Thrombolysis in Myocardial Infarction trial
t-PA 5 tissue-type plasminogen activator
Figure 1. Patency rates as a function of time to treatment (Rx).
Table 1. Baseline Characteristics
t-PA
(n 5 237)
SK
(n 5 244)
p
Value
Age (yr) 56.1 6 10 54.8 6 12 NS
Men 86.5 86.5 NS
History of smoking 78.9 72.1 NS
Diabetes mellitus 11.4 9.0 NS
Cholesterol .240 mg/dl 45.6 40.6 NS
Hypertension 32.1 27 NS
Family history of CAD 32.9 40.6 NS
Time from pain to treatment (min) 171 6 79 175 6 68 NS
Time from pain to CCU admission (min) 186 6 82 195 6 107 NS
Anterior location 49.9 51.2 NS
Previous myocardial infarction 8.9 7.8 NS
Cardiogenic shock at admission 3.4 1.6 NS
Prehospital thrombolysis 49.4 54.9 NS
Data are presented as the mean value 6 SD or percentage of patients.
CAD 5 coronary artery disease; CCU 5 coronary care unit; SK 5 streptokinase;
t-PA 5 tissue-type plasminogen activator.
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on the probability of patency can be considered as constant for
t-PA. This multivariate analysis gave similar results regardless
of whether patency was defined as TIMI flow grade 2 and 3
(Table 2) or as TIMI flow grade 3 alone (data not shown).
When patients receiving t-PA were categorized as having
received treatment ,3 or $3 h after pain onset, the patency
rate was similar regardless of whether TIMI flow grades 2 and
3 were pooled (71.6% vs. 71.9%, p 5 NS) or whether TIMI
flow grade 3 alone was considered to indicate patency (61.9%
vs. 57.3%, p 5 NS). In contrast, the efficacy of SK was
significantly higher among patients treated ,3 versus $3 h
after pain onset (86.9% vs. 59.4% for pooled TIMI flow grades
2 and 3, p 5 0.0001 and 81.7% vs. 53.6% for TIMI flow grade
3 alone, p 5 0.0001) (Fig. 2). No baseline characteristics other
than time to treatment were significantly associated with
90-min patency. Among patients receiving t-PA, there was no
difference in the average time to treatment between patients
with patent (TIMI flow grade 2 or 3) infarct-related arteries
and patients with occluded infarct-related arteries at 90 min
(172 6 79 vs. 169 6 79 min, respectively, p 5 NS). In contrast,
among patients receiving SK, those who had a patent infarct-
related artery at 90 min had been treated, on average, earlier
than patients with occluded arteries (163 6 54 vs. 218 6
90 min, respectively, p 5 0.0001).
Discussion
The results of this analysis suggest that the efficacy of SK
but not t-PA in restoring early coronary patency after intrave-
nous thrombolysis is markedly reduced when patients are
treated .3 h after pain onset. There were no differences in
baseline characteristics that could have accounted for the
different behavior of t-PA and SK. This confirms a preliminary
observation in the TIMI-1 study (4). A similar negative corre-
lation between the time from symptom onset to treatment and
the patency rate has been reported with anistreplase (5,6) and
urokinase (11), suggesting that this phenomenon is common to
“nonfibrin-specific” thrombolytic agents. In the Thrombolytic
trial of Eminase in Acute Myocardial infarction (TEAM-1)
study (5), the 90-min reperfusion rate dropped from 60% if
anistreplase was given ,4 h after onset to 33% if it was given
later after 4 h. These observations are consistent with the
notion that more recent clots may be more susceptible to
thrombolysis with SK and related fibrinolytic agents, possibly
owing to lesser fibrin cross-linking. In contrast, older clots may
be more resistant to thrombolytic agents (12) through continu-
ing fibrin polymerization and plasminogen activator inhibitor
release by platelets. In contrast, t-PA appears to lyse fresh and
older clots equally efficiently. This is consistent with in vitro
observations (12) and may be related to the much higher fibrin
affinity with t-PA than with other plasminogen activators, as
well as to the differences in the spatial distribution of fibrino-
lytic components during thrombolysis. Using confocal micros-
copy, Sakharov et al. (13) have shown that the depth of the
prelysis zone of a plasma clot is dependent on the fibrin-
binding properties of the plasminogen activator used and
corresponds to the depth of penetration of the activator into
the clot. Given its high affinity for fibrin, t-PA penetrates less
deeply than nonfibrin-specific agents and remains confined to
a very sharp and thin front of lysis (13). In the case of older,
retracted thrombi, these differences in spatial penetration by
plasminogen activators may translate into substantial differ-
ences in infarct-related artery patency. This indicates that the
time between pain onset and therapy should be taken into
account when comparing patency rates between thrombolytic
regimens.
This finding has several potential implications. First, be-
cause t-PA has no clear superiority over SK in terms of survival
when patients are treated .6 h after pain onset (14), this
would tend to confirm the hypothesis that SK may be beneficial
in ways other than restoring early patency (e.g., decreased
blood viscosity). Second, the strong relation between time to
treatment and survival after thrombolysis may not be related
solely to earlier and therefore more effective myocardial
salvage when patency is reestablished, but may also be related,
at least in the case of SK, to higher patency rates when
treatment is given early.
Figure 2. Patency rates of TIMI flow grades 2 and 3 when patients
were categorized as having received treatment ,3 h (open bars) or
$3 h (solid bars) after symptom onset.
Table 2. Effect of Time to Treatment on Patency Rate: Logistic
Regression Analysis
Variable
Variable
Estimate
Standard
Error
p Value
(Wald test)
A. Initial model
Intercept 0.9144 0.3488 0.0088
Treatment (SK 5 1, t-PA 5 0) 2.4755 0.5991 0.0001
Time (min) 0.000344 0.00186 0.8536
Interaction (treatment 3 time) 20.0118 0.00299 0.0001
B. Final model
Intercept 0.9731 0.1456 0.0001
Treatment (SK 5 1, t-PA 5 0) 2.4169 0.5083 0.0001
Interaction (treatment 3 time) 20.0115 0.00233 0.0001
Abbreviations as in Table 1.
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Study limitations. The main limitation of this study is that
it is based on a retrospective analysis of data accumulated for
other purposes (validation of noninvasive markers of reperfu-
sion and patency studies). However, there was no bias in
recruitment toward one treatment or the other and there was
no bias in the selection of patients for angiography, as all
patients who entered both studies underwent 90-min angiog-
raphy. Angiographic patency has been shown to be poorly
reproducible, with a notable overlap between patients with
TIMI flow grades 2 and 3 (15). However, separation of TIMI
flow grades 0 to 1 and 2 to 3 is more reliable, showing excellent
interobserver agreement in the analysis by Gibson et al. (15),
with a kappa value of 0.84 6 0.05. In addition, the difference
between the patency rates obtained when SK was given ,3 and
.3 h after symptom onset held, regardless of the criterion used
to define angiographic patency. Finally, our blinded grading of
angiograms guarantees unbiased analysis.
Conclusions. In acute myocardial infarction, the time be-
tween the onset of pain and the beginning of thrombolytic
therapy strongly influences the patency rates obtained with SK
but not with accelerated t-PA.
We are grateful to D. D. Young for help with preparation of the manuscript and
to J. Ph. Collet and T. Lecompte for helpful discussions.
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